Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Plasma cell 2 Other hematologic neoplasm 2 Lymphoid 1 Endocrine 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Interventions

Ipilimumab 123 pembrolizumab 101 Nivolumab 100 aldesleukin 89 Cyclophosphamide 85 fludarabine phosphate 64 Interleukin-2 58 Dacarbazine 57 3-ingenyl angelate 42 Vemurafenib 39 Temozolomide 39 Imiquimod 39 trametinib 37 sargramostim 37 Peripheral Blood Stem Cell Transplantation 36 incomplete Freund's adjuvant 35 dabrafenib 32 fludarabine 31 Radiotherapy 31 Aminolevulinic Acid 30 Bevacizumab 29 Carboplatin 28 Whole-Body Irradiation 25 Photochemotherapy 25 Paclitaxel 25 Filgrastim 25 Biopsy 25 Interferon-alpha 24 Cisplatin 23 Sorafenib 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Anti-Bacterial Agents × Dermatologic × Clear all

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

14 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡